Cargando…
P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430561/ http://dx.doi.org/10.1097/01.HS9.0000970092.68730.83 |
| _version_ | 1785090994291605504 |
|---|---|
| author | Kelly, Richard Houghton, Nicola Munir, Talha Muus, Petra Youngs, Nora Aurand, Lisa Senk, Brian Pavani, Rodrigo Perlee, Lorah Souttou, Amal Griffin, Morag |
| author_facet | Kelly, Richard Houghton, Nicola Munir, Talha Muus, Petra Youngs, Nora Aurand, Lisa Senk, Brian Pavani, Rodrigo Perlee, Lorah Souttou, Amal Griffin, Morag |
| author_sort | Kelly, Richard |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430561 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104305612023-08-17 P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB Kelly, Richard Houghton, Nicola Munir, Talha Muus, Petra Youngs, Nora Aurand, Lisa Senk, Brian Pavani, Rodrigo Perlee, Lorah Souttou, Amal Griffin, Morag Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430561/ http://dx.doi.org/10.1097/01.HS9.0000970092.68730.83 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Kelly, Richard Houghton, Nicola Munir, Talha Muus, Petra Youngs, Nora Aurand, Lisa Senk, Brian Pavani, Rodrigo Perlee, Lorah Souttou, Amal Griffin, Morag P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title | P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title_full | P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title_fullStr | P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title_full_unstemmed | P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title_short | P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title_sort | p797: a phase 2, open-label study evaluating the safety and efficacy of combination pozelimab and cemdisiran therapy in patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430561/ http://dx.doi.org/10.1097/01.HS9.0000970092.68730.83 |
| work_keys_str_mv | AT kellyrichard p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT houghtonnicola p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT munirtalha p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT muuspetra p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT youngsnora p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT aurandlisa p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT senkbrian p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT pavanirodrigo p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT perleelorah p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT souttouamal p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT griffinmorag p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab |